Denali Therapeutics Inc. - Common Stock (DNLI)
Frequently Asked Questions About Denali Therapeutics Inc. - Common Stock (DNLI)
Does Denali Therapeutics have any approved drugs?
As of October 2023, Denali Therapeutics has not yet received FDA approval for any drugs. However, they are actively engaged in multiple clinical trials aimed at securing regulatory approval for their investigational therapies.
Has Denali Therapeutics Inc. partnered with any other companies?
Yes, Denali Therapeutics Inc. has established numerous collaborations with various pharmaceutical and biotechnology companies, such as its partnership with Sanofi, to leverage their combined expertise in pursuing innovative therapies and accelerating development timelines.
How can investors stay informed about Denali Therapeutics?
Investors can stay informed about Denali Therapeutics by following company press releases, financial reports, and announcements regarding clinical trial updates. Additionally, they can participate in investor calls and review information available on the company's official website and financial news outlets.
How does Denali Therapeutics measure clinical success?
Denali Therapeutics measures clinical success through rigorous clinical trials and studies designed to evaluate the efficacy and safety of its drug candidates. Success is determined by analyzing data from these trials, including patient responses and biomarkers relevant to neurodegenerative diseases.
On which stock exchange is Denali Therapeutics Inc. listed?
Denali Therapeutics Inc. is listed on the Nasdaq stock exchange under the ticker symbol DNLI. This allows investors to buy and sell shares of the company and participate in its growth.
What are neurodegenerative diseases?
Neurodegenerative diseases are conditions characterized by the progressive degeneration of the nervous system, leading to a decline in cognitive and motor functions. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), all of which are targeted by Denali’s research and development efforts.
What are some key products in Denali's pipeline?
Denali Therapeutics has several key products in its pipeline, including DNL201, which targets ALS (Amyotrophic lateral sclerosis), and DNL310 being developed for a range of lysosomal storage disorders. These products reflect the company's focus on innovative approaches to treating serious neurodegenerative conditions.
What are the future goals of Denali Therapeutics?
The future goals of Denali Therapeutics include advancing their drug candidates through clinical trials, obtaining regulatory approvals, expanding their pipeline of potential therapies, and ultimately providing effective treatments for patients suffering from neurodegenerative diseases.
What are the primary challenges facing Denali Therapeutics?
Primary challenges for Denali Therapeutics include navigating the complex regulatory landscape for drug approval, competing in the highly competitive biotech space, and addressing the inherent uncertainties of developing therapies for neurodegenerative diseases.
What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. Their mission is to harness their proprietary drug delivery technologies and deep scientific expertise to create effective treatments for conditions like Alzheimer's disease, Parkinson's disease, and other related disorders.
What financial support has Denali received?
Denali Therapeutics has raised significant funding through various financing rounds, including its initial public offering (IPO) in 2017. This financial support has been instrumental in developing its drug pipeline and advancing clinical studies.
What is Denali Therapeutics’ approach to research and development?
Denali Therapeutics adopts a science-driven approach to research and development, emphasizing understanding the biology of neurodegenerative diseases. This involves exploring new therapeutic pathways, developing innovative delivery mechanisms, and conducting robust clinical evaluations.
What is Denali’s mission?
Denali Therapeutics' mission is to develop transformative therapies for patients with neurodegenerative diseases by employing innovative drug delivery technologies and rigorous research. They aim to make a significant impact on patient lives through their scientific advancements.
What is Denali’s strategy for addressing the market need in neurodegenerative diseases?
Denali Therapeutics’ strategy for addressing the market need in neurodegenerative diseases involves focusing on innovative drug delivery mechanisms, targeting previously inaccessible pathways, and leveraging collaborations to enhance their research capabilities and expedite product development.
What technologies does Denali utilize in its drug development?
Denali Therapeutics employs advanced technology platforms, including their proprietary Transport Vehicle (TV) platform, which enhances the delivery of therapeutics across the blood-brain barrier. This technology enables more effective treatment of neurodegenerative disorders that affect the brain.
When was Denali Therapeutics Inc. founded?
Denali Therapeutics Inc. was founded in 2015 by a team of experienced biopharmaceutical executives and scientists. Their goal was to create a focused company dedicated to advancing treatments for neurodegenerative diseases.
Where is Denali Therapeutics Inc. headquartered?
Denali Therapeutics Inc. is headquartered in South San Francisco, California. This prime location allows them to remain close to a vibrant biotechnology ecosystem and a pool of talent in the area.
Who are the founders of Denali Therapeutics Inc.?
The founders of Denali Therapeutics Inc. are particular leaders in the biotech industry, including Kevin D. O’Connor and other esteemed scientists and executives. Their combined expertise supports the company’s mission to address difficult-to-treat neurodegenerative diseases.
Who is the current CEO of Denali Therapeutics?
As of my last knowledge update, the current CEO of Denali Therapeutics Inc. is Ryan Watts, PhD. He has played a crucial role in advancing the company's pipeline and expanding its research initiatives.
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 13.74
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 1.67B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 121.64M shares outstanding.